In summary, these data show that selective inhibition of the PDGF-CC/PDGFRα signaling pathway resulted in a reduction in stroke infarct volume and myofibroblast expansion similar to that seen with imatinib treatment, thus potentially offering a targeted treatment approach for patients with ischemic stroke. The gene discussed is CXCR1; the disease is stroke disorder.